Search research articles
Contact Us
Filters
Showing results (271-280 of 283) with videos related to
Page
of 29
Sort By:
Life (Basel, Switzerland)
|
September 24, 2020
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report
Ourania E Tsitsilonis, Dimitrios Paraskevis, Evi Lianidou, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Blood Advances
|
August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials
Maria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Leukemia
|
February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2020
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Mark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, et al.
British Journal of Haematology
|
March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Laura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Nature Genetics
|
May 21, 2025
Genomic landscape of multiple myeloma and its precursor conditions
Jean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, et al.
Blood Cancer Journal
|
March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Shaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
The Lancet. Oncology
|
September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
The New England Journal of Medicine
|
May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Cyrille Touzeau, Roberto Mina, Hang Quach, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 283) with videos related to
Sort By:
Page
of 29
Life (Basel, Switzerland)
|
September 24, 2020
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report
Ourania E Tsitsilonis, Dimitrios Paraskevis, Evi Lianidou, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Blood Advances
|
August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials
Maria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Leukemia
|
February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2020
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Mark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, et al.
British Journal of Haematology
|
March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Laura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Nature Genetics
|
May 21, 2025
Genomic landscape of multiple myeloma and its precursor conditions
Jean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, et al.
Blood Cancer Journal
|
March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Shaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
The Lancet. Oncology
|
September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
The New England Journal of Medicine
|
May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Cyrille Touzeau, Roberto Mina, Hang Quach, et al.
Page
of 29